Lonza  announced the addition of Redberry SAS to its family, strengthening its position as a global leader in quality control solutions for the pharmaceutical and biotechnology industries. The integration brings Redberry SAS’s innovative Red One™ Rapid Microbiology Platform into Lonza’s portfolio, enhancing its capabilities in rapid sterility and bioburden testing.

The Red One™ Rapid Microbiology Platform is designed to accelerate microbiological quality control workflows by delivering faster, automated, and highly precise detection of microbial contamination. With this addition, Lonza aims to help customers streamline quality control processes, accelerate product release timelines, and maintain the highest standards of quality and regulatory compliance.

The expanded offering reinforces Lonza’s commitment to advancing automation and innovation in pharmaceutical quality control. By combining Lonza’s global expertise with Redberry SAS’s breakthrough rapid microbiology technology, the company is setting a new benchmark for speed, precision, and reliability in microbiological testing.

Rapid microbiology solutions play a critical role in ensuring product safety while enabling pharmaceutical and biotech manufacturers to reduce time-to-market. The integration of Redberry SAS’s technology enables faster sterility and bioburden testing, improving operational efficiency and providing customers with greater confidence in their quality control processes.

This strategic addition further strengthens Lonza’s ability to support customers across the full development and manufacturing lifecycle, providing advanced solutions that meet evolving regulatory requirements and industry needs.

Lonza and Redberry SAS share a vision of transforming microbiological quality control through innovation, automation, and scientific excellence. Together, they will continue to drive advancements that enhance pharmaceutical manufacturing efficiency while safeguarding patient safety.